TONY LUONGO MD
Prescription History 1164520417
Urology in Boston, MA

NPI Status: Active since September 20, 2006

Contact Information

800 WASHINGTON ST
BOX 7105
BOSTON, MA
ZIP 02111
Phone: (617) 636-5000

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for TONY LUONGO MD, an active Urology specialist practicing in Boston, MA. Our medical registry currently tracks 7 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 434 documented patient claims. Among these therapy options, the most frequently utilized medication is Tamsulosin Hcl, which accounts for 167 claims alone.

Medication Index


Cefuroxime

Generic Formulation: Cefuroxime AxetilSpecialty: Urology
Provider Metrics Summary
Total Claims 31
30-Day Fills 31.0
Days Supply 95
MA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills27.8
Peer Average Days Supply244
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $153.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.95

State Avg Cost Per Claim

$24.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cephalosporin antibiotic.

Therapeutic Applications

Cefuroxime is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Ciprofloxacin Hcl

Generic Formulation: Ciprofloxacin HclSpecialty: Urology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 93
MA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.7
Peer Average Days Supply197
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $69.63 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.80

State Avg Cost Per Claim

$6.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A broad-spectrum antimicrobial carboxyfluoroquinoline.

Therapeutic Applications

This medication is used to treat eye infections. Ciprofloxacin belongs to a class of drugs called quinolone antibiotics. It works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Dutasteride

Generic Formulation: DutasterideSpecialty: Urology
Provider Metrics Summary
Total Claims 12
30-Day Fills 34.0
Days Supply 1,020
MA State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills58.5
Peer Average Days Supply1,733
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.0% less volume than the regional standard for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $263.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$21.93

State Avg Cost Per Claim

$64.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.

Therapeutic Applications

This medication is used in men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It works by reducing the size of the enlarged prostate. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate frequently or urgently (including during the middle of the night). It may also reduce the need for surgery to treat BPH. Dutasteride is not approved for prevention of prostate cancer. It may slightly increase the risk of developing a very serious form of prostate cancer. Talk to your doctor about the benefits and risks. This medication should not be used by women or children.

Finasteride

Generic Formulation: FinasterideSpecialty: Urology
Provider Metrics Summary
Total Claims 112
30-Day Fills 298.0
Days Supply 8,882
MA State Average Benchmarks
Peer Average Claims56.0
Peer Average 30-Day Fills130.2
Peer Average Days Supply3,839
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 100.0% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,216.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.79

State Avg Cost Per Claim

$17.73

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.

Therapeutic Applications

Finasteride is used to shrink an enlarged prostate (benign prostatic hyperplasia or BPH) in adult men. It may be used alone or taken in combination with other medications to reduce symptoms of BPH and may also reduce the need for surgery. Finasteride may improve symptoms of BPH and provide benefits such as decreased urge to urinate, better urine flow with less straining, less of a feeling that the bladder is not completely emptied, and decreased nighttime urination. This medication works by decreasing the amount of a natural body hormone (DHT) that causes growth of the prostate. Finasteride is not approved for prevention of prostate cancer. It may slightly increase the risk of developing a very serious form of prostate cancer. Talk to your doctor about the benefits and risks. Women and children should not use this medication.

Myrbetriq

Generic Formulation: MirabegronSpecialty: Urology
Provider Metrics Summary
Total Claims 80
30-Day Fills 120.0
Days Supply 3,535
MA State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills74.8
Peer Average Days Supply2,074
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 45.5% more claims than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $53,717.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$671.47

State Avg Cost Per Claim

$561.34

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bladder problems (overactive bladder, neurogenic detrusor overactivity). Overactive bladder is a problem with how your bladder stores urine. Neurogenic detrusor overactivity is a bladder control condition caused by brain, spinal cord, or nerve problems. Symptoms of these conditions may include frequent urination, strong sudden urges to urinate that are hard to control, or involuntary loss of urine (incontinence). Mirabegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder and neurogenic detrusor overactivity.

Oxybutynin Chloride Er

Generic Formulation: Oxybutynin ChlorideSpecialty: Urology
Provider Metrics Summary
Total Claims 20
30-Day Fills 32.0
Days Supply 932
MA State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills65.7
Peer Average Days Supply1,925
Conservative Utilization

This provider writes prescriptions for this formulation 39.4% less frequently than the standard regional baseline metric for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $846.04 across this reporting matrix range.

Provider Avg Cost Per Claim

$42.30

State Avg Cost Per Claim

$50.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This is a long-acting form of oxybutynin that is used to treat overactive bladder and urinary conditions. It relaxes the muscles in the bladder to help decrease problems of urgency and frequent urination. Oxybutynin belongs to a class of drugs known as antispasmodics. This medication is also used to treat children 6 years of age and older who have an overactive bladder due to certain nerve disorders (such as spina bifida).

Tamsulosin Hcl

Generic Formulation: Tamsulosin HclSpecialty: Urology
Provider Metrics Summary
Total Claims 167
30-Day Fills 433.0
Days Supply 12,971
MA State Average Benchmarks
Peer Average Claims74.0
Peer Average 30-Day Fills163.8
Peer Average Days Supply4,817
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 125.7% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,438.27 across this reporting matrix range.

Provider Avg Cost Per Claim

$32.56

State Avg Cost Per Claim

$24.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Tamsulosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Tamsulosin belongs to a class of drugs known as alpha blockers. Do not use this medication to treat high blood pressure.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like TONY LUONGO MD provides transparency into local medical care patterns within Boston, MA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Urology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.